- Home
- MCB vs MYGN Comparison
MCB vs MYGN Comparison
Compare MCB & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCB
- MYGN
- Stock Information
- Founded
- MCB 1999
- MYGN 1991
- Country
- MCB United States
- MYGN United States
- Employees
- MCB N/A
- MYGN N/A
- Industry
- MCB Major Banks
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- MCB Finance
- MYGN Health Care
- Exchange
- MCB Nasdaq
- MYGN Nasdaq
- Market Cap
- MCB 685.1M
- MYGN 756.5M
- IPO Year
- MCB 2017
- MYGN 1995
- Fundamental
- Price
- MCB $66.61
- MYGN $6.29
- Analyst Decision
- MCB Buy
- MYGN Hold
- Analyst Count
- MCB 2
- MYGN 14
- Target Price
- MCB $82.00
- MYGN $13.27
- AVG Volume (30 Days)
- MCB 148.8K
- MYGN 1.0M
- Earning Date
- MCB 10-23-2025
- MYGN 11-03-2025
- Dividend Yield
- MCB 0.90%
- MYGN N/A
- EPS Growth
- MCB 8.50
- MYGN N/A
- EPS
- MCB 5.80
- MYGN N/A
- Revenue
- MCB $261,456,000.00
- MYGN $825,300,000.00
- Revenue This Year
- MCB $15.57
- MYGN $0.06
- Revenue Next Year
- MCB $13.99
- MYGN $5.68
- P/E Ratio
- MCB $11.55
- MYGN N/A
- Revenue Growth
- MCB 1.27
- MYGN 0.21
- 52 Week Low
- MCB $47.08
- MYGN $3.76
- 52 Week High
- MCB $81.33
- MYGN $19.60
- Technical
- Relative Strength Index (RSI)
- MCB 36.12
- MYGN 30.88
- Support Level
- MCB $65.00
- MYGN $6.22
- Resistance Level
- MCB $67.05
- MYGN $8.38
- Average True Range (ATR)
- MCB 2.39
- MYGN 0.43
- MACD
- MCB -0.40
- MYGN -0.24
- Stochastic Oscillator
- MCB 14.43
- MYGN 8.33
About MCB Metropolitan Bank Holding Corp.
Metropolitan Bank Holding Corp is a bank holding company. It provides a broad range of business, commercial, and retail banking products and services to small businesses, middle-market enterprises, public entities, and individuals in the New York metropolitan area. The services provided by the company include deposits, trade finance, cash management solutions, savings, electronic banking, cards, and others. The company also provides various lending products such as acquisition loans, construction loans, and lines of credit, for retail, office, hospitality, multifamily, mixed-use, warehouse and distribution, and specialty-use properties. The bank derives its revenue in the form of interest income on loans.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.